Puma Biotechnology Inc (PBYI) — Titan Protect Analysis

PBYI

Puma Biotechnology Inc

Healthcare · ·

$7.03

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$356M

Total market value of the company

Trailing P/E

14.57

Reasonably valued

Forward P/E

19.99

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.6%

Year-over-year revenue change

Profit Margin

10.7%

How much profit the company keeps from each dollar of revenue

ROE

21.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

-29% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A fo

https://www.pumabiotechnology.com

Country: United States Employees: 179 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.815

Good returns relative to risk taken

Kelly Fraction

0.0456

Modest edge detected — smaller position warranted

Calmar Ratio

0.875

Acceptable balance between returns and drawdown risk

Annual Return

38.7%

Historical annualised return based on price data

Max Drawdown

-44.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.23

Moves slightly more than the broader market

52W High

$7.90

11% below the year high

52W Low

$3.03

132% above the year low

Avg Volume

283,676

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.42

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

74.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-8.5%

Profit from core operations before interest and tax

Free Cash Flow

$44M

Positive — the business generates more cash than it spends

Revenue (TTM)

$227M

Total revenue over the last 12 months

Net Income

$24M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$5.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go